期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

沙利度胺联合IP方案二线治疗小细胞肺癌的临床研究

暂未订购
导出
摘要 目的观察沙利度胺联合IP方案二线治疗敏感性复发的小细胞肺癌(SCLC)的近期疗效及毒副反应。方法选择一线EP方案治疗失败且在3～6个月内出现进展患者24例,随机分为2组,IP组12例予伊立替康60 mg/m2静滴第1,8天,DDP 25 mg/m2静滴第1—3天;联合组12例予IP方案联合沙利度胺,沙利度胺剂量50 mg/d起睡前顿服,之后每3 d增加25 mg,至100 mg/d维持,至少连续口服42 d。2组均21 d为1个周期,2个周期评价疗效。结果联合组与IP组患者近期有效率(RR)分别是42%(5/12)和33%(4/12),临床受益率(CBR)分别为83%(10/12)和67%(8/12),2组比较无显著性差异(P均>0.05)。2组患者的主要毒副反应为骨髓抑制(包括粒细胞减少及血小板减少)、恶心呕吐、肝功能异常及腹泻。联合组Ⅲ～Ⅳ度恶心呕吐发生率明显低于IP组(P=0.032)。结论沙利度胺联合IP方案二线治疗敏感性复发的小细胞肺癌有较好疗效,沙利度胺可以减少Ⅲ～Ⅳ度恶心呕吐的发生。
作者 刘非 孟祥玲 王国华 史福敏 赵恩锋
机构地区 河北省沧州中西医结合医院
出处 《现代中西医结合杂志》 CAS 2013年第3期277-278,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 肺肿瘤 沙利度胺 伊立替康 顺铂
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1柳影,程颖,张彩霞,左学荣.伊立替康联合顺铂与拓扑替康联合顺铂二线治疗小细胞肺癌的比较研究[J].临床肿瘤学杂志,2008,13(11):984-987. 被引量：12
  • 2Zhon Y,Gwadry FG,Reinhold WC,et al. Transcriptional. regulation of mitotic genes by camptothecin, induced DNA damage : microarray analysis of dose- and time-dependent effects [ J ]. Cancer Res, 2002,62 (6) : 1688 - 1695.
  • 3Noda K,Nishiwaki Y, Kawahara M,et al. Lrinotecan plus eisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer[J]. N Engt JMed,2002,346(2):85-91.
  • 4Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase m trial comparing irinoteean/eisplatin with etopaside/eisplatin in patients with previously untreated extensive-stage disease small cell lung cancer[ J]. J Clin 0ncol,2006,24( 13 ) :2038 - 2043.
  • 5Natal ERB, Lara PN, Chansky K, et al. A randomized phase 111 tri- al comparing ifinoteean/eisplatin(IP) witll etopaside/eisplatin(EP) in patients(pts)with previously untreated extensive stage small cell lung cancer( E - SCLC) [ J ]. J Clin Oneol, 2008,26 ( 20 Suppl) : 7512.
  • 6Okishio K, Furuse K, Kawahara M, et al. A phase II study of iri- noteean and cisplatin in previously treated small cell lung cancer [J]. Proc Am soc Olin Onco1,1998,17(497 a) :1914.
  • 7韩亚光,麻丽军,崔彦芝,曹世堂,付华斌,张建军.沙立度胺单独及联合多柔比星对人肝癌细胞株HepG2过氧化物酶体增殖物激活受体γ、环氧合酶-2表达的影响[J].华北国防医药,2009,21(2):24-27. 被引量：2
  • 8Lin AY,Brophy N, Fisher GA, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma[J]. Cancer, 2005,103(1) :119 -125.
  • 9Dowlati A, Subbiah S, Cooney M. Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy [ J ]. Lung Cancer, 2007,56 ( 3 ) : 377 - 381.
  • 10Lee SM,Woll PJ,Rudd R,et al. Anti-angiogenic therapy using tha- lidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial [ J ]. J Natl Cancer Inst, 2009,101 ( 15 ) : 1049 - 1057.

二级参考文献17

  • 1何晓燕,张敏,陈智超,游泳,田蕾,邹萍.PPAR-γ在肺癌中的表达及在肺癌凋亡中的作用研究[J].中国肺癌杂志,2006,9(1):35-39. 被引量：13
  • 2Zhou Y, Gwadry FG, Reinhold WC, et al. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage : microarray analysis of dose-and time-dependent effects[ J]. Cancer Res ,2002,62 (6) : 1688 - 1695.
  • 3Ardizzoni A, Manegold C, Debruyne C, et al. European organization for research and treatment of cancer ( EORTC ) 08975 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small-cell lung cancer[J]. Clin Cancer Res, 2003, 9:143 - 150.
  • 4O'Brien M, Ciuleanu T, Tsekov H, et al. Phase Ⅲ trial comparing supportive care alone with oral topotecan in patients with relapsed small-cell lung cancer[ J]. J Clin Oncol, 2006, 24:5441 - 5447.
  • 5Ichiki M, Gohara R, Rikimaru T, et al. Combination chemotherapy with irinotcan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: A phase H study [ J ]. Chemotherapy, 2003,49 ( 4 ) : 200.
  • 6Argiris A, Murren JR. Advances in chemotherapy for small cell lung cancer, single-agent activity of newer agents [ J]. Cancer, 2001, 7(3) :228 -235.
  • 7Hanna N, Bunn PA, Langer C, et al. Randomized phase Ⅲ trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer [ J ]. J Clin Oncol, 2006, 24 ( 13 ) :2038 - 2043.
  • 8Kato M, Kusumi T, Tsuchida S, et al. Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone [ J ]. J Cancer Res Clin Onco1,2004,130 ( 2 ) :73-79.
  • 9Fajas L, Egler V, Reiter R, et al. PPAR gamma controls cell proliferation and apoptosis in an RB-dependent manner [ J ]. Oncogene, 2003,22 ( 27 ) :4186-4193.
  • 10Wang C, Pattabiraman N,Zhou J N. Cyclin D1 repressionof peroxisome proliferator-activated receptor gamma expression and transactivation[ J ]. Mol Cell Biol, 2003,23 ( 17 ) : 6159- 6173.

共引文献12

现代中西医结合杂志
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部